Literature DB >> 9781747

The introduction of Haemophilus influenzae type b immunization into the United Kingdom: practical steps to assure success.

D M Salisbury1.   

Abstract

Haemophilus influenzae type b (Hib) vaccine was introduced into the routine childhood immunization program in the UK in October, 1992. The implementation was coordinated on a national basis, taking account of market research of the information needs of both the public and health professionals. Vaccine distribution arrangements were linked to the scheduling of children for immunization, which was implemented through a national computerized system of calling children for immunization. All children commencing immunization were called for three doses of Hib vaccine. Children < 1 year of age were called back for three doses of vaccine; children >1 but <4 years were called for one dose. No boosters were given. National coverage from the outset of the campaign exceeded 90%; it is now 95% and the incidence of invasive Hib infection has declined by >95%. Some of the lessons learned from the UK introduction may be of relevance to other countries presently considering the implementation of Hib immunization into their routine immunization programs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9781747     DOI: 10.1097/00006454-199809001-00009

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  2 in total

1.  Decrease in effectiveness of routine surveillance of Haemophilus influenzae disease after introduction of conjugate vaccine: comparison of routine reporting with active surveillance system.

Authors:  B Olowokure; J Hawker; I Blair; N Spencer
Journal:  BMJ       Date:  2000-09-23

Review 2.  The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Authors:  Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.